Wall Street analyst estimates for Prelude Therapeutics Incorporated (PRLD): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 1 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.38 |
Valuation Ratios
| Price / Book | 3.24 |
| EV / EBITDA | -5.13 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | $7.0M | $12.1M |
| Cost of Revenue | $149000 | 0 | 0 | 0 | 0 | 0 | 0 | $1.7M |
| Gross Profit | -$149000 | 0 | 0 | 0 | 0 | 0 | $7.0M | $10.4M |
| Research & Development | $12.6M | $24.3M | $48.2M | $86.8M | $92.9M | $103.4M | $118.0M | $94.3M |
| Selling, General & Admin | $2.4M | $3.8M | $10.6M | $27.0M | $30.7M | $28.9M | $28.7M | $22.4M |
| Operating Expenses | $15.0M | $28.1M | $58.8M | $113.7M | $123.5M | $132.3M | $146.7M | $115.0M |
| Operating Income | -$15.0M | -$28.1M | -$58.8M | -$113.7M | -$123.5M | -$132.3M | -$139.7M | -$104.6M |
| EBITDA | -$14.8M | -$27.7M | -$58.2M | -$110.8M | -$114.1M | -$120.7M | -$125.4M | -$97.8M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$14.7M | -$27.6M | -$56.9M | -$111.7M | -$115.4M | -$121.8M | -$127.2M | -$99.5M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$14.7M | -$27.6M | -$56.9M | -$111.7M | -$115.4M | -$121.8M | -$127.2M | -$99.5M |
| EPS | $-9.31 | $-0.85 | $-1.30 | $-2.33 | $-2.27 | $-2.02 | $-1.68 | $-1.29 |
| EPS (Diluted) | $-9.31 | $-0.85 | $-1.30 | $-2.33 | $-2.27 | $-2.02 | $-1.68 | $-1.29 |
| Shares Outstanding (Diluted) | $1.6M | $32.4M | $43.7M | $47.6M | $47.4M | $60.4M | $75.8M | $77.0M |
Price
| Price | $4.47 |
| Market Cap | $254M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AVTX · CRBU · ENTA · EPRX · FHTX · IMRX · IVA
Explore sector: Healthcare · Biotechnology
More sections of PRLD: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks